- Funding to help advance three drug candidates in clinical trials in 2021 -

- Company has raised $81 million in funding to date –

BALTIMORE, MARYLAND, June 24, 2021 – Gliknik Inc., an immunology company dedicated to patients with cancer and autoimmune disorders, today announced that it has successfully completed an $11.5 million Series C Preferred Stock financing. First In Ventures (FIV) led the Series C with SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings also participating. The proceeds are targeted to progress the growing pipeline of Gliknik product candidates.Gliknikhas secured $81 million to date to advance its programs.

“We believe that Gliknik has created several potential best-in-class mid-stage assets,” said Scott Roth, managing partner of FIV.“This capital will help unlock the potential of these compounds and uniquely positions Gliknik to make a difference forpatients with cancer or autoimmune disorders.”

Read the full release from Gliknik.